Evidence map›Paper›PMID 35346349›Full record

ArticleStem cell research & therapy2022

A transgenic mouse embryonic stem cell line for puromycin selection of V0

Jennifer Pardieck, Manwal Harb, Shelly E Sakiyama-Elbert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recombinant Cell-Permeable PuromycinJournal of microbiology and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jennifer PardieckDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton St., Austin, TX, 78712-1139, USA.
Manwal HarbDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton St., Austin, TX, 78712-1139, USA.
Shelly E Sakiyama-ElbertDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton St., Austin, TX, 78712-1139, USA. sakiyama@utexas.edu.ORCID 0000-0003-4832-5851

Funding

DEVELOPING NEW TOOLS TO UNDERSTAND THE ROLE OF INTERNEURONS IN REWIRING AFTER SPINAL CORD INJURY.R01NS090617 · NINDS · WASHINGTON UNIVERSITY · PI SAKIYAMA-ELBERT, SHELLY ELESE · 2015 to 2019
$1.6M
Determining the Potential of V0 Interneurons in Promoting Functional Recovery After Spinal Cord Injury in a Rat ModelF31NS100432 · NINDS · UNIVERSITY OF TEXAS AT AUSTIN · PI PARDIECK, JENNIFER · 2017 to 2017
$35k
NINDS NIH HHS F31 NS100432NINDS NIH HHS F31NS100432NINDS NIH HHS R01 NS090617NINDS NIH HHS R01NS090617
6 · The paper itself

Abstract

backgroundSpinal interneurons (INs) relay sensory and motor control information between the brain and body. When this relay circuitry is disrupted from injury or disease, it is devastating to patients due to the lack of native recovery in central nervous system (CNS) tissues. Obtaining a purified population of INs is necessary to better understand their role in normal function and as potential therapies in CNS. The ventral V0 (V0

methodsThe transgenic Evx1-PAC mESC line was created by CRISPR-Cas9-mediated insertion of puromycin-N-acetyltransferase (PAC) into the locus of V0

resultsV0

conclusionsEvx1-PAC mESCs can be used to purify V0

Indexed as

InterneuronsMouse Embryonic Stem CellsAnimalsHomeodomain ProteinsHumansMiceMice, TransgenicMotor NeuronsPuromycinEvx1 protein, mouseHomeodomain ProteinsPuromycinNeuronal networksSelectable transgenic mESCsV0V spinal interneurons

Identifiers

PMID35346349
PMCPMC8962475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.